Previous studies have reported that TMT1A is downregulated in multiple cancers, including melanoma32 and renal cancer,42 where its low expression correlates with poor prognosis, reduced immune infiltration, and inferior responses to immunotherapy. The gene discussed is TMT1A; the disease is renal carcinoma.